Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mapping the Safety Profile of Histone Deacetylase Inhibitors in Children with Cancer.

Clinical epigenetics·2026
Same author

PC3/Tis21/BTG2 and BTG1 genes: regulators of the cell cycle and neurogenesis, as well as tumor suppressors in malignant brain tumors.

Frontiers in cell and developmental biology·2026
Same author

Hydroxytyrosol Mitigates Anxiety-Like Behaviors After a Traumatic Experience in Aged Mice in Parallel With Increased Neurogenesis in the Ventral and Dorsal Dentate Gyrus, and Preservation of Gut Microbiota Composition.

Journal of neurochemistry·2026
Same author

Implementing the National Vaccination Plan in people with HIV in Italy: A survey among ICONA centres.

HIV medicine·2026
Same author

The Role of Immune Dysregulation Markers in Cardiovascular Risk of People Living with HIV: Association Among Intima Media Changes, CD4/CD8 Ratio, and CD4+ Cell Count Nadir.

Viruses·2026
Same author

Impact of nutritional source modality on weight loss and BMI reduction after hematopoietic stem cell transplantation.

Frontiers in oncology·2026

相关实验视频

Updated: Jun 11, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

820

开发用于儿科固体瘤的CAR T细胞疗法.

Gabriele Canciani1,2, Francesco Fabozzi1, Claudia Pinacchio1

  • 1Department of Hematology, Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.

Paediatric drugs
|October 9, 2024
PubMed
概括

化学抗原受体 (CAR) T细胞疗法对神经母细胞瘤等儿科固体瘤显示出前景. 创新策略旨在克服更广泛,更有效的癌症治疗的挑战.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

464
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K

相关实验视频

Last Updated: Jun 11, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

820
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

464
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.2K

科学领域:

  • 免疫治疗是一种免疫疗法.
  • 在瘤学瘤学.
  • 细胞疗法细胞疗法

背景情况:

  • 化学抗原受体 (CAR) T细胞已经改变了血液癌症治疗.
  • 固体瘤,特别是儿科瘤,对CAR T细胞疗效提出了独特的生物学挑战.
  • 这些挑战包括抗原异质性,T细胞透不良以及免疫抑制瘤微环境.

研究的目的:

  • 审查儿童固体瘤中CAR-T细胞治疗的进展和挑战.
  • 突出GD2向神经母细胞瘤中CAR T细胞的潜力.
  • 讨论创新的工程策略,以提高CAR T细胞的功效和持久性.

主要方法:

  • 对实体瘤中CAR-T细胞治疗的临床前证据和临床试验数据的审查.
  • 专注于用于神经母细胞瘤治疗的针对GD2的CAR T细胞.
  • 在体内改善CAR T细胞功能的工程策略的分析.

主要成果:

  • 卡尔-T细胞在对抗固体瘤方面表现出临床前的有效性,但在体内存在局限性.
  • 向GD2的CAR T细胞在高危神经母细胞瘤患者中显示出有前途的结果.
  • 创新的工程方法表明了改进和可扩展的CAR T细胞疗法的潜力.

结论:

  • 卡尔T细胞疗法具有治疗侵袭性儿科固体瘤的巨大潜力.
  • 克服免疫抑制性瘤微环境和增强T细胞持久性是关键的挑战.
  • 未来CAR T细胞工程的进步可能会导致更有效的免疫治疗策略用于儿科癌症.